In response to the latest surge of COVID-19 cases due to the delta variant, I want to draw your attention to the three previous MS-Selfie Newsletters I have recently done to cover several issues relevant to people with MS. I suggest you read them.
Are COVID-19 booster vaccines necessary? It is clear that the SARS-CoV-2 delta variant is a partial vaccine escape variant. This means that people with MS who have been vaccinated in the past are likely to need a booster.
COVID-19 vaccines and DMTs: What is happening to people with MS on DMTs getting vaccinated with the COVID-19 vaccines. Are they immune or not?
COVID-19 vaccination: Countering the misinformation and disinformation about vaccination in MS
I have also done a newsletter and two case studies on switching from anti-CD20 therapies to highlight the complexities of the issues raised by anti-CD20 therapies and vaccination.
Switching from an anti-CD20: the why and the how: Many people with multiple sclerosis on ocrelizumab or rituximab are wanting to switch to another disease-modifying therapy. In this Newsletter, I explain why and how to do it.
Case study: Switching from Ocrelizumab to Alemtuzumab: In this case study, I discuss the nuts and bolts of switching from ocrelizumab (anti-CD20) to alemtuzumab (anti-CD52) for vaccine readiness and perceived higher efficacy.
Case study: Ocrelizumab to Teriflunomide switch: Prof G discusses the case for using ocrelizumab as an induction therapy followed by teriflunomide maintenance therapy. This is how he envisages using the class of anti-CD20 therapies in the future.
Subscriptions: I am raising funds from subscriptions to administer the MS-Selfie Newsletter and microsite. The subscriptions are being used to hire a part-time medical writer and proofreader and an administrator to curate and transfer the contents of the Newsletter onto the companion MS-Selfie microsite. So if you find these Newsletters helpful and can afford to subscribe I would urge you to do so; it will help me and the MS community. Many of the improvements you have suggested for MS-Selfie need time. I simply don’t have the time to do all the work myself. Thank you.
General Disclaimer: Please note that the opinions expressed here are those of Professor Giovannoni and do not necessarily reflect the positions of Barts and The London School of Medicine and Dentistry nor Barts Health NHS Trust. The advice is intended as general advice and should not be interpreted as being personal clinical advice. If you have problems please tell your own healthcare professional who will be able to help you.
Share this post
COVID-19 vaccines and MS
Share this post
In response to the latest surge of COVID-19 cases due to the delta variant, I want to draw your attention to the three previous MS-Selfie Newsletters I have recently done to cover several issues relevant to people with MS. I suggest you read them.
Are COVID-19 booster vaccines necessary? It is clear that the SARS-CoV-2 delta variant is a partial vaccine escape variant. This means that people with MS who have been vaccinated in the past are likely to need a booster.
COVID-19 vaccines and DMTs: What is happening to people with MS on DMTs getting vaccinated with the COVID-19 vaccines. Are they immune or not?
COVID-19 vaccination: Countering the misinformation and disinformation about vaccination in MS
I have also done a newsletter and two case studies on switching from anti-CD20 therapies to highlight the complexities of the issues raised by anti-CD20 therapies and vaccination.
Switching from an anti-CD20: the why and the how: Many people with multiple sclerosis on ocrelizumab or rituximab are wanting to switch to another disease-modifying therapy. In this Newsletter, I explain why and how to do it.
Case study: Switching from Ocrelizumab to Alemtuzumab: In this case study, I discuss the nuts and bolts of switching from ocrelizumab (anti-CD20) to alemtuzumab (anti-CD52) for vaccine readiness and perceived higher efficacy.
Case study: Ocrelizumab to Teriflunomide switch: Prof G discusses the case for using ocrelizumab as an induction therapy followed by teriflunomide maintenance therapy. This is how he envisages using the class of anti-CD20 therapies in the future.
Leave a comment
Subscriptions: I am raising funds from subscriptions to administer the MS-Selfie Newsletter and microsite. The subscriptions are being used to hire a part-time medical writer and proofreader and an administrator to curate and transfer the contents of the Newsletter onto the companion MS-Selfie microsite. So if you find these Newsletters helpful and can afford to subscribe I would urge you to do so; it will help me and the MS community. Many of the improvements you have suggested for MS-Selfie need time. I simply don’t have the time to do all the work myself. Thank you.
MS-Selfie
Conflicts of Interest
Twitter
LinkedIn
Medium
General Disclaimer: Please note that the opinions expressed here are those of Professor Giovannoni and do not necessarily reflect the positions of Barts and The London School of Medicine and Dentistry nor Barts Health NHS Trust. The advice is intended as general advice and should not be interpreted as being personal clinical advice. If you have problems please tell your own healthcare professional who will be able to help you.